Trends and challenges in one of the largest areas of contemporary drug development - presented by industry professionals with a track record of discovering new drugs and treatments.
Trends and challenges in one of the largest areas of contemporary drug development - presented by industry professionals with a track record of discovering new drugs and treatments.
Dario Doller, PhD, has over 30 years of experience in pharmaceutical research, contributing to numerous clinical compounds and a marketed drug. He has authored over 100 articles and patents and is Chief Scientific Officer at Modulate Bio. Kevin J. Hodgetts, PhD, is Associate Professor of Neurology at Harvard Medical School and Head of Medicinal Chemistry and Director of the Lab for Drug Discovery in Neuroscience (LDDN) at Brigham and Women's Hospital.
Inhaltsangabe
PART 1: CURRENT STATUS AND THERAPY OVERVIEW Drug discovery in the Century of Biology Academic vs. Industrial CNS drug discovery: An evolving relationship The role of Venture Capital in drug discovery Spin-off companies The NIH role catalyzing the discovery of novel treatments PART 2: KEY QUESTIONS FOR CONTEMPORARY CNS DRUG DISCOVERY The end: defining CNS diseases (molecular vs phenotype) Target selection in the treatment of CNS diseases The use of animal models in brain drug research Biomarkers in CNS drug discovery PET imaging in CNS drug discovery PART 3: PSYCHEDELIC-INSPRIRED DRUG DISCOVERY Update on ketamine, esketamine, arketamine Non-hallucinogenic antidepressants Cannabinoids as therapeutics for brain disease PART 4: UNION MAKES STRENGTH: COMBINING DRUGS TO PRODUCE NOVEL CNS THERAPEUTICS Xanomeline-trospium for schizophrenia Olanzapine-samidorphan Dextromethorphan-bupropion Levodopa prodrug Apomorphine PART 5: EMERGING CHEMICAL MODALITIES FOR BRAIN DISEASES PROTACs in CNS drug discovery Small molecule allosteric modulators Progress using biologics drugs for CNS diseases (CGRP migraine, Anti-amyloid antibodies, MSA/PD and a-SYN antibodies) Using mechanistic studies for CNS diseases What is the best surrogate of brain penetration? Brain cancer treatments (brain penetration of kinase inhibitor) PART 6: EPILOGUE Treating brain disease in the next decade
PART 1: CURRENT STATUS AND THERAPY OVERVIEW Drug discovery in the Century of Biology Academic vs. Industrial CNS drug discovery: An evolving relationship The role of Venture Capital in drug discovery Spin-off companies The NIH role catalyzing the discovery of novel treatments PART 2: KEY QUESTIONS FOR CONTEMPORARY CNS DRUG DISCOVERY The end: defining CNS diseases (molecular vs phenotype) Target selection in the treatment of CNS diseases The use of animal models in brain drug research Biomarkers in CNS drug discovery PET imaging in CNS drug discovery PART 3: PSYCHEDELIC-INSPRIRED DRUG DISCOVERY Update on ketamine, esketamine, arketamine Non-hallucinogenic antidepressants Cannabinoids as therapeutics for brain disease PART 4: UNION MAKES STRENGTH: COMBINING DRUGS TO PRODUCE NOVEL CNS THERAPEUTICS Xanomeline-trospium for schizophrenia Olanzapine-samidorphan Dextromethorphan-bupropion Levodopa prodrug Apomorphine PART 5: EMERGING CHEMICAL MODALITIES FOR BRAIN DISEASES PROTACs in CNS drug discovery Small molecule allosteric modulators Progress using biologics drugs for CNS diseases (CGRP migraine, Anti-amyloid antibodies, MSA/PD and a-SYN antibodies) Using mechanistic studies for CNS diseases What is the best surrogate of brain penetration? Brain cancer treatments (brain penetration of kinase inhibitor) PART 6: EPILOGUE Treating brain disease in the next decade
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/5800/1497
USt-IdNr: DE450055826
